Healthy

81 competing products in clinical development for Healthy.

Pipeline by Phase

Pre-clinical1

Phase 180

All Products (81)

Product	Company	Stage	Status	Hype
AZD0837	AstraZeneca	Phase 1	Completed	33
Valsartan	Novartis	Phase 1	Completed	33
ALT02 + EU-licensed Herceptin + US-licensed Herceptin	Alteogen	Phase 1	Completed	33
Lasmiditan + Placebo	Eli Lilly	Phase 1	Completed	33
LOXO-783	Eli Lilly	Phase 1	Completed	33
LY2541546 - IV + LY2541546 - SC + Placebo	Eli Lilly	Phase 1	Completed	33
LY3867070 + Placebo	Eli Lilly	Phase 1	Recruiting	33
Mirikizumab Test + Mirikizumab Test + Mirikizumab Reference	Eli Lilly	Phase 1	Completed	33
[¹⁴C]-LY3484356 + LY3484356 + [¹⁴C]-LY3484356 (IV)	Eli Lilly	Phase 1	Completed	33
Ixekizumab	Eli Lilly	Phase 1	Completed	33
Lasmiditan + Propranolol	Eli Lilly	Phase 1	Completed	33
LY3537982 + Digoxin + Rosuvastatin + Midazolam + Midazolam	Eli Lilly	Phase 1	Completed	33
LY3074828	Eli Lilly	Phase 1	Completed	33
[(11)C] MePPEP	Eli Lilly	Phase 1	Completed	33
LY3451838 + LY3451838 + LY3451838 + LY3451838 + LY3451838 + LY3451838 + LY3451838 + Placebo	Eli Lilly	Phase 1	Completed	33
LY3537031	Eli Lilly	Phase 1	Recruiting	33
LY2963016	Eli Lilly	Phase 1	Completed	33
Baricitinib suspension + Baricitinib tablet	Eli Lilly	Phase 1	Completed	33
[14C]-LY3866288 + LY3866288 + [14C]-LY3866288	Eli Lilly	Phase 1	Completed	33
Selpercatinib + Moxifloxacin + Placebo	Eli Lilly	Phase 1	Completed	33
LY3502970 + Esomeprazole	Eli Lilly	Phase 1	Completed	33
LY3375880 IV + LY3375880 SC + Placebo IV + Placebo SC	Eli Lilly	Phase 1	Completed	33
Midazolam + Selpercatinib	Eli Lilly	Phase 1	Completed	33
LY3214996 + [14C]-LY3214996	Eli Lilly	Phase 1	Completed	33
LY3871801 + Placebo	Eli Lilly	Phase 1	Completed	33
LY3305677 + Placebo	Eli Lilly	Phase 1	Completed	33
Selpercatinib	Eli Lilly	Phase 1	Completed	33
LY3209590 (SC) + LY3209590 (IV)	Eli Lilly	Phase 1	Completed	33
LY3819253 + Placebo	Eli Lilly	Phase 1	Completed	33
[14C]-LY3556050	Eli Lilly	Phase 1	Completed	33
LY3540378 + Placebo + LY3540378	Eli Lilly	Phase 1	Completed	33
Orforglipron + Midazolam + Quinidine	Eli Lilly	Phase 1	Completed	33
Mirikizumab	Eli Lilly	Phase 1	Recruiting	33
LY3437943	Eli Lilly	Phase 1	Completed	33
LY4086940 + Placebo + LY4086940	Eli Lilly	Phase 1	Recruiting	33
Pegilodecakin	Eli Lilly	Phase 1	Completed	33
Rosuvastatin + Selpercatinib	Eli Lilly	Phase 1	Completed	33
LY4100511	Eli Lilly	Phase 1	Completed	33
V930	Merck	Phase 1	Completed	33
E2609 + Placebo	Eisai	Phase 1	Completed	33
LY3971297 + Placebo + LY3971297 IV	Eli Lilly	Phase 1	Recruiting	33
Selpercatinib + Omeprazole	Eli Lilly	Phase 1	Completed	33
LY3471851	Eli Lilly	Phase 1	Completed	33
LY3372689	Eli Lilly	Phase 1	Completed	33
Lebrikizumab + Placebo	Eli Lilly	Phase 1	Completed	33
LY4065967	Eli Lilly	Phase 1	Completed	33
CTL02 + CTL0201 + CTL0202	Celltrion	Phase 1	Completed	33
CT-L01 12.5/1,000 mg + CT-L01 12.5/1,000 mg	Celltrion	Phase 1	Completed	33
CT-P6 SC + EU-Approved Herceptin SC	Celltrion	Phase 1	Active	33
L04RD1 + L04TD1 + L04TD1 + L04RD1	Celltrion	Phase 1	Completed	33
CT-G11 + CT-G20 + CT-G11 Placebo + CT-G20 Placebo	Celltrion	Phase 1	Completed	33
CT-P17 + US-licensed Humira + EU-approved Humira	Celltrion	Phase 1	Completed	33
CT-L01 + Alogliptin Benzoate 25 mg + Metformin HCl XR 1,000 mg	Celltrion	Phase 1	Completed	33
CT-L01 12.5/500 mg + Alogliptin Benzoate 12.5 mg + Metformin HCl XR 500 mg	Celltrion	Phase 1	Completed	33
L04RD1 + L04TD2 + L04TD2 + L04RD1	Celltrion	Phase 1	Completed	33
CT-P39 + EU-approved Xolair + CT-P39 + EU-approved Xolair + US-licensed Xolair	Celltrion	Phase 1	Completed	33
CT-P17 + CT-P17	Celltrion	Phase 1	Completed	33
CSL112 + Placebo	CSL	Phase 1	Completed	32
UT-15C	United Therapeutics	Phase 1	Completed	30
TP-05 (lotilaner oral), fasted group + TP-05 (lotilaner oral), high-fat group + TP-05 (lotilaner oral), low-fat group	Tarsus Pharmaceuticals	Phase 1	Completed	28
TP-03 (Lotilaner Ophthalmic Solution), 0.25%	Tarsus Pharmaceuticals	Phase 1	Completed	28
TP-05 (lotilaner oral capsules) + Placebo	Tarsus Pharmaceuticals	Phase 1	Completed	28
MBX 2109 (Part A) + MBX 2109 (Part B) + Placebo	MBX Biosciences	Phase 1	Completed	28
Dabigatran etexilate + Rosuvastatin + Daridorexant	Idorsia	Phase 1	Completed	28
Daridorexant + Famotidine + Efavirenz	Idorsia	Phase 1	Completed	28
Open-label TRV734 125 mg + TRV734 blinded + Oxycodone IR 10 mg + Placebo	Trevena	Phase 1	Completed	25
TRV130 + Moxifloxacin + Placebo	Trevena	Phase 1	Completed	25
Radiolabeled TRV130	Trevena	Phase 1	Completed	25
TRV130A + Dextrose in Water	Trevena	Phase 1	Completed	25
TRV734	Trevena	Phase 1	Completed	25
Nalmefene	Tharimmune	Phase 1	Completed	25
THB335 single dose + Single dose placebo + THB335 fasted/fed + Placebo fasted/fed + THB335 multiple dose + Multiple dose placebo	Third Harmonic Bio	Phase 1	Completed	25
AL002	Alector	Phase 1	Completed	25
AL001	Alector	Phase 1	Completed	25
AL101	Alector	Phase 1	Completed	25
AL003	Alector	Phase 1	Completed	25
SYNB8802 + Placebo	Synlogic	Phase 1	Completed	25
CDX-6114 + Placebo	Codexis	Phase 1	Completed	25
CDX-6114 + Placebo	Codexis	Phase 1	Completed	25
SYNB1934 + SYNB1618	Synlogic	Phase 1	Completed	25
Propranolol + Pseudoephedrine	Eli Lilly	Pre-clinical	Completed	23